Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 1/2016

01-02-2016 | Evidence-Based Review

Efficacy and Safety of 308-nm Monochromatic Excimer Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review with Meta-Analysis

Authors: Celso Lopes, Virginia Fernandes Moça Trevisani, Tamara Melnik

Published in: American Journal of Clinical Dermatology | Issue 1/2016

Login to get access

Abstract

Background

Various phototherapy methods are used to treat vitiligo; however, the recent emergence of new devices has heightened debate concerning the best treatment method.

Objective

We aimed to systematically review and meta-analyze published data comparing the efficacy and adverse effects of monochromatic excimer lamps versus excimer laser and narrowband ultraviolet B (NB-UVB) in treating vitiligo.

Methods

A systematic search of PubMed, EMBASE, LILACS, Cochrane Central Register of Controlled Trials (CENTRAL), and clinical trials registries identified randomized controlled trials that included vitiligo patients, regardless of age, sex, or study language. We evaluated studies comparing excimer lamps with excimer laser or NB-UVB phototherapy.

Results

The review included six studies (411 patients, 764 lesions). No study found significantly different efficacy between excimer lamps and excimer laser using the outcomes of ≥50 % repigmentation [risk ratio (RR) = 0.97, 95 % confidence interval (CI) 0.84–1.11] and ≥75 % repigmentation (RR = 0.96, 95 % CI 0.71–1.30). Likewise, no study found significant differences between excimer lamps and NB-UVB (RR = 1.14, 95 % CI 0.88–1.48 for ≥50 % repigmentation; RR = 1.81, 95 % CI 0.11–29.52 for ≥75 % repigmentation). Adverse effects were mild, including pruritus, burning sensation, and dryness, none of which interrupted treatment.

Conclusions

To our knowledge, this is the first systematic review of the efficacy and safety of excimer lamp treatment for vitiligo. Excimer lamps, excimer laser, and NB-UVB are all safe and effective in repigmentation of vitiligo lesions. Safety, effectiveness, and cost are considerations when choosing treatment.

PROSPERO Registration Number

CRD42014015237.
Appendix
Available only for authorised users
Literature
1.
2.
Ding GZ, Zhao WE, Li X, Gong QL, Lu Y. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin. Arch Dermatol Res. 2015;307:281–9.PubMedCrossRef
3.
Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol. 2011;38:419–31.PubMedCrossRef
4.
5.
Taieb A, Alomar A, Böhm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168:5–19.PubMedCrossRef
6.
Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65:473–91.PubMedCrossRef
7.
Teovska Mitrevska N, Eleftheriadou V, Guarneri F. Quality of life in vitiligo patients. Dermatol Ther. 2012;25:S28–31.
8.
Sampogna F. Life course impairment and quality of life over time. Curr Probl Dermatol. 2013;44:47–51.PubMedCrossRef
9.
Mishra N, Rastogi MK, Gahalaut P, Agrawal S. Dermatology specific quality of life in vitiligo patients and its relation with various variables: a hospital based cross-sectional study. J Clin Diagn Res. 2014;8:YC01–3.
10.
Krüger C, Schallreuter KU. Stigmatisation, avoidance behaviour and difficulties in coping are common among adult patients with vitiligo. Acta Derm Venereol. 2015;95:553–8.PubMedCrossRef
11.
Ezzedine K, Grimes PE, Meurant JM, Seneschal J, Léauté-Labrèze C, Ballanger F, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173:607–9.PubMedCrossRef
12.
Bin Saif GA, Al-Balbeesi AO, Binshabaib R, Alsaad D, Kwatra SG, Alzolibani AA, et al. Quality of life in family members of vitiligo patients: a questionnaire study in Saudi Arabia. Am J Clin Dermatol. 2013;14:489–95.PubMedCrossRef
13.
14.
15.
Spritz RA. Modern vitiligo genetics sheds new light on an ancient disease. J Dermatol. 2013;40:310–8.PubMedCrossRef
16.
Ghafourian A, Ghafourian S, Sadeghifard N, Mohebi R, Shokoohini Y, Nezamoleslami S, et al. Vitiligo: symptoms, pathogenesis and treatment. Int J Immunopathol Pharmacol. 2014;27:485–9.PubMed
17.
Speeckaert R, Speeckaert MM, van Geel N. Why treatments do(n’t) work in vitiligo: an autoinflammatory perspective. Autoimmun Rev. 2015;14:332–40.PubMedCrossRef
18.
Lin X, Tang LY, Fu WW, Kang KF. Childhood vitiligo in China: clinical profiles and immunological findings in 620 cases. Am J Clin Dermatol. 2011;12:277–81.PubMedCrossRef
19.
Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP, et al. Role of oxidative stress and autoimmunity in onset and progression of vitiligo. Exp Dermatol. 2014;23:352–3.PubMedCrossRef
20.
Zedan H, Abdel-Motaleb AA, Kassem NM, Hafeez HA, Hussein MR. Low glutathione peroxidase activity levels in patients with vitiligo. J Cutan Med Surg. 2015;19:144–8.PubMed
21.
Güntaş G, Engin B, Ekmekçi ÖB, Kutlubay Z, Ekmekci H, Songür A, et al. Evaluation of advanced oxidation protein products, prooxidant-antioxidant balance, and total antioxidant capacity in untreated vitiligo patients. Ann Dermatol. 2015;27:178–83.PubMedPubMedCentralCrossRef
22.
Camara-Lemarroy CR, Salas-Alanis JC. The role of tumor necrosis factor-α in the pathogenesis of vitiligo. Am J Clin Dermatol. 2013;14:343–50.PubMedCrossRef
23.
Kumar R, Parsad D, Kanwar AJ. Role of apoptosis and melanocytorrhagy: a comparative study of melanocyte adhesion in stable and unstable vitiligo. Br J Dermatol. 2011;164:187–91.PubMedCrossRef
24.
Kumar R, Parsad D. Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces. Indian J Dermatol Venereol Leprol. 2012;78:19–23.PubMedCrossRef
25.
Kanwar AJ, Mahajan R, Parsad D. Low-dose oral mini-pulse dexamethasone therapy in progressive unstable vitiligo. J Cutan Med Surg. 2013;17:259–68.PubMedCrossRef
26.
27.
Du J, Wang XY, Ding XL, Xu QX, Chen Z, Chang JM, et al. Long-term efficacy and safety of tacrolimus ointment in the treatment of vitiligo. J Dermatol. 2013;40:935–6.PubMedCrossRef
28.
Cavalié M, Ezzedine K, Fontas E, Montaudié H, Castela E, Bahadoran P, et al. Maintenance therapy of adult vitiligo with 0.1 % tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135:970–4.PubMedCrossRef
29.
Newman MD, Silverberg NB. Once-daily application of calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment for repigmentation of facial vitiligo. Cutis. 2011;88:256–9.PubMed
30.
Hossani-Madani A, Halder R. Treatment of vitiligo: advantages and disadvantages, indications for use and outcomes. G Ital Dermatol Venereol. 2011;146:373–95.PubMed
31.
Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52:491–6.PubMedCrossRef
32.
Lim HW, Grimes PE, Lebwohl M. Indications and limitations of afamelanotide for treating vitiligo-reply. JAMA Dermatol. 2015;151:350.PubMedCrossRef
33.
Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatol. 2015;151:42–50.PubMedCrossRef
34.
Singh C, Parsad D, Kanwar AJ, Dogra S, Kumar R. Comparison between autologous noncultured extracted hair follicle outer root sheath cell suspension and autologous noncultured epidermal cell suspension in the treatment of stable vitiligo: a randomized study. Br J Dermatol. 2013;169:287–93.PubMedCrossRef
35.
Bacigalupi RM, Postolova A, Davis RS. Evidence-based, non-surgical treatments for vitiligo: a review. Am J Clin Dermatol. 2012;13:217–37.PubMedCrossRef
36.
Machado Filho CD. Timoner FR. Epidermal curettage technique (ECT) for tissue harvest from the donor area for melanocyte autologous grafting in cases of vitiligo. An Bras Dermatol. 2014;89:681–3.PubMedPubMedCentralCrossRef
37.
Sapam R, Agrawal S, Dhali TK. Systemic PUVA vs. narrowband UVB in the treatment of vitiligo: a randomized controlled study. Int J Dermatol. 2012;51:1107–15.PubMedCrossRef
38.
Akar A, Tunca M, Koc E, Kurumlu Z. Broadband targeted UVB phototherapy for localized vitiligo: a retrospective study. Photodermatol Photoimmunol Photomed. 2009;25:161–3.PubMedCrossRef
39.
Yazdani Abyaneh M, Griffith RD, Falto-Aizpurua L, Nouri K. Narrowband ultraviolet B phototherapy in combination with other therapies for vitiligo: mechanisms and efficacies. J Eur Acad Dermatol Venereol. 2014;28:1610–22.
40.
Hallaji Z, Ghiasi M, Eisazadeh A, Damavandi MR. Evaluation of the effect of disease duration in generalized vitiligo on its clinical response to narrowband ultraviolet B phototherapy. Photodermatol Photoimmunol Photomed. 2012;28:115–9.PubMedCrossRef
41.
Akdeniz N, Yavuz IH, Gunes Bilgili S, Ozaydın Yavuz G, Calka O. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasone and calcipotriol in vitiligo. J Dermatolog Treat. 2014;25:196–9.PubMedCrossRef
42.
Alhowaish AK, Dietrich N, Onder M, Fritz K. Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review. Lasers Med Sci. 2013;28:1035–41.PubMedCrossRef
43.
Park KK, Liao W, Murase JE. A review of monochromatic excimer light in vitiligo. Br J Dermatol. 2012;167:468–78.PubMedCrossRef
44.
Lee BW, Schwartz RA, Hercogová J, Valle Y, Lotti TM. Vitiligo road map. Dermatol Ther. 2012;25(Suppl 1):S44–56.PubMedCrossRef
45.
Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol. 2011;35(Suppl 2):147–51.PubMed
46.
Lee CH, Wu SB, Hong CH, Yu HS, Wei YH. Molecular mechanisms of UV-induced apoptosis and its effects on skin residential cells: the implication in UV-based phototherapy. Int J Mol Sci. 2013;14:6414–35.PubMedPubMedCentralCrossRef
47.
Korobko IV. Review of current clinical studies of vitiligo treatments. Dermatol Ther. 2012;25(Suppl 1):S17–27.PubMedCrossRef
48.
Itoi S, Tanemura A, Nishioka M, Sakimoto K, Iimuro E, Katayama I. Evaluation of the clinical safety and efficacy of a newly developed 308-nm excimer lamp for vitiligo vulgaris. J Dermatol. 2012;39:559–61.PubMedCrossRef
49.
Mehraban S, Feily A. 308 nm excimer laser in dermatology. J Lasers Med Sci. 2014;5:8–12.
50.
Al-Shobaili HA. Treatment of vitiligo patients by excimer laser improves patients’ quality of life. J Cutan Med Surg. 2015;19:50–6.PubMedCrossRef
51.
Mouzakis JA, Liu S, Cohen G. Rapid response of facial vitiligo to 308nm excimer laser and topical calcipotriene. J Clin Aesthet Dermatol. 2011;4:41–4.PubMedPubMedCentral
52.
53.
54.
Kaliyadan F, Ashique KT. Optimizing the efficacy of targeted phototherapy by marking early vitiligo lesions after visualizing under a Wood’s lamp. J Am Acad Dermatol. 2014;71:e69.PubMedCrossRef
55.
Lotti TM, Hercogová J, Schwartz RA, Tsampau D, Korobko I, Pietrzak A, et al. Treatments of vitiligo: what’s new at the horizon. Dermatol Ther. 2012;25(Suppl 1):S32–40.PubMedCrossRef
56.
Hamzavi IH, Lim HW, Syed ZU. Ultraviolet-based therapy for vitiligo: what’s new? Indian J Dermatol Venereol Leprol. 2012;78:42–8.PubMedCrossRef
57.
Lee KY, Jeon SY, Hong JW, Choi KW, Lee CY, Choi SJ, et al. Endothelin-1 enhances the proliferation of normal human melanocytes in a paradoxical manner from the TNF-α-inhibited condition, but tacrolimus promotes exclusively the cellular migration without proliferation: a proposed action mechanism for combination therapy of phototherapy and topical tacrolimus in vitiligo treatment. J Eur Acad Dermatol Venereol. 2013;27:609–16.PubMedCrossRef
58.
Noborio R, Morita A. Preferential induction of endothelin-1 in a human epidermal equivalent model by narrow-band ultraviolet B light sources. Photodermatol Photoimmunol Photomed. 2010;26:159–61.PubMedCrossRef
59.
Goldstein NB, Koster MI, Hoaglin LG, Spoelstra NS, Kechris KJ, Robinson SE, et al. Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors. J Invest Dermatol. 2015;135:2068–76.PubMedPubMedCentralCrossRef
60.
Eby JM, Kang HK, Tully ST, Bindeman WE, Peiffer DS, Chatterjee S, et al. CCL22 to activate treg migration and suppress depigmentation in vitiligo. J Invest Dermatol. 2015;135:1574–80.PubMedCrossRef
61.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. http://​handbook.​cochrane.​org. Accessed Oct 26 2015.
62.
Verhaeghe E, Lodewick E, van Geel N, Lambert J. Intrapatient comparison of 308-nm monochromatic excimer light and localized narrow-band UVB phototherapy in the treatment of vitiligo: a randomized controlled trial. Dermatology. 2011;223:343–8.PubMedCrossRef
63.
Casacci M, Thomas P, Pacifico A, Bonnevalle A, Paro Vidolin A, Leone G. Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy (311–313 nm) in the treatment of vitiligo–a multicentre controlled study. J Eur Acad Dermatol Venereol. 2007;21:956–63.PubMedCrossRef
64.
Shi Q, Li K, Fu J, Wang Y, Ma C, Li Q, et al. Comparison of the 308-nm excimer laser with the 308-nm excimer lamp in the treatment of vitiligo–a randomized bilateral comparison study. Photodermatol Photoimmunol Photomed. 2013;29:27–33.PubMedCrossRef
65.
Le Duff F, Fontas E, Giacchero D, Sillard L, Lacour JP, Ortonne JP, et al. 308-nm excimer lamp vs. 308-nm excimer laser for treating vitiligo: a randomized study. Br J Dermatol. 2010;163:188–92.PubMed
66.
Yan Y, Li J, Wang R, Zhong RP, Guo LH, Zhu MH. A randomized comparative clinical trial of 308 monochromatic excimer light and 311 nm narrow-band ultraviolet in treating vitiligo [in Chinese]. J Clin Dermatol. 2013;2:120–3.
67.
Liu YB, Yang YF, Song LX, Shan YH, Wang Y, Ma TQ, et al. Comparison of 308 nm excimer laser and 308 nm excimer lamp in treatment of vitiligo [in Chinese]. Clin Misdiagnosis Mistherapy. 2013;6:58–61.
68.
Lan CC, Yu HS, Lu JH, Wu CS, Lai HC. Irradiance, but not fluence, plays a crucial role in UVB-induced immature pigment cell development: new insights for efficient UVB phototherapy. Pigment Cell Melanoma Res. 2013;26:367–76.PubMedCrossRef
69.
Sun Y, Wu Y, Xiao B, Li L, Chen HD, Gao XH. Treatment of 308-nm excimer laser on vitiligo: a systemic review of randomized controlled trials. J Dermatolog Treat. 2015;26:347–53.PubMedCrossRef
70.
Xiao BH, Wu Y, Sun Y, Chen HD, Gao XH. Treatment of vitiligo with NB-UVB: a systematic review. J Dermatolog Treat. 2015;26:340–6.PubMedCrossRef
Metadata
Title
Efficacy and Safety of 308-nm Monochromatic Excimer Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review with Meta-Analysis
Authors
Celso Lopes
Virginia Fernandes Moça Trevisani
Tamara Melnik
Publication date
01-02-2016
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 1/2016
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-015-0164-2

Other articles of this Issue 1/2016

American Journal of Clinical Dermatology 1/2016 Go to the issue

Review Article

Mal de Meleda: A Focused Review

Original Research Article

US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

Original Research Article

Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials

Review Article

Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

Review Article

Merkel Cell Carcinoma: Current Issues Regarding Diagnosis, Management, and Emerging Treatment Strategies

Original Research Article

Second Primary Malignancies in CTCL Patients from 1992 to 2011: A SEER-Based, Population-Based Study Evaluating Time from CTCL Diagnosis, Age, Sex, Stage, and CD30+ Subtype